O-823

O-823

Identifiers
IUPAC name 7-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]hept-5-ynenitrile
PubChem (CID)	9863194
ChemSpider	8038890 Y
Chemical and physical data
Formula	C23H27NO2
Molar mass	349.465 g/mol
3D model (Jmol)	Interactive image
SMILES Oc2cc(CC#CCCCC#N)cc(OC1(C)C)c2C3C1CC=C(C)C3
InChI InChI=1S/C23H27NO2/c1-16-10-11-19-18(13-16)22-20(25)14-17(9-7-5-4-6-8-12-24)15-21(22)26-23(19,2)3/h10,14-15,18-19,25H,4,6,8-9,11,13H2,1-3H3/t18-,19-/m1/s1 Y Key:MZMMIGOIGWVGEH-RTBURBONSA-N Y
(verify)

O-823 is a drug which is a cannabinoid derivative that is used in scientific research. It is described as a mixed agonist/antagonist at the cannabinoid receptor CB₁, meaning that it acts as an antagonist when co-administered alongside a more potent CB₁ agonist, but exhibits weak partial agonist effects when administered by itself.^[1][2][3]

References

1. ↑ Pertwee RG, Fernando SR, Griffin G, Ryan W, Razdan RK, Compton DR, Martin BR. Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. European Journal of Pharmacology. 1996 Nov 14;315(2):195-201. PMID 8960884
2. ↑ Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. British Journal of Pharmacology. 1999 Apr;126(7):1575-84. doi:10.1038/sj.bjp.0702469 PMID 10323589
3. ↑ Griffin G, Wray EJ, Martin BR, Abood ME. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology. 1999 Oct;128(3):684-8. doi:10.1038/sj.bjp.0702806 PMID 10516649